Skip to main content
Clinical Trials/JPRN-UMIN000001050
JPRN-UMIN000001050
Completed
Phase 2

A phase II study of the combination of Rituximab, Mitoxantrone, Etoposide, and Prednisolone for relapsed elderly patients with diffuse large B-cell lymphoma (R-MEP07) - A phase II study of the combination of Rituximab, Mitoxantrone, Etoposide, and Prednisolone for relapsed elderly patients with lymphoma (R-MEP07)

Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)0 sites40 target enrollmentMarch 1, 2008

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Diffuse large B-cell lymphoma
Sponsor
Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)
Enrollment
40
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 1, 2008
End Date
July 30, 2015
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) CNS involvement 2\) History of glaucoma 3\) History of severe drug allergy 4\) Active infectious diseases 5\) HIV or HTLV\-1 positive 6\) HBs antigen or HCV antibody positive 7\) Significant complications which include cardiac dysfunction, liver cirrhosis, uncontrolled diabetes, renal failure 8\) Interstitial pneumonitis or fibrosis 9\) History of other active malignancy 10\) Severe mental disorder 11\) Regular use of systemic steroids 12\) Inadequate physical condition, as diagnosed by primary physician

Outcomes

Primary Outcomes

Not specified

Similar Trials